Investing in DURECT Corporation (DRRX)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)363.7827669
Intrinsic value (DCF)0.89-32
Graham-Dodd Method0.00-100
Graham Formula60.044483

Company description

DRRX, also known as Durect Corporation, is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for chronic diseases. The company is headquartered in California, with offices in the United Kingdom and Japan. DRRX was founded in 1998 and has since been a pioneer in utilizing technology to improve patient outcomes. Their primary focus is on developing products that can enhance the safety, solubility, and delivery of drugs. The company's most significant achievement to date is obtaining FDA approval for their first commercial product, Posimir, which is a non-opioid pain relief treatment. DRRX has a robust pipeline of other potential drugs in various stages of development, including treatments for post-surgical pain, acute migraines, and hepatic diseases. The company's commitment to innovation and improving the lives of those suffering from chronic illnesses has positioned them as a leader in the biopharmaceutical industry. With a dedicated team of scientists, researchers, and business professionals, DRRX continues to make significant strides towards developing groundbreaking treatments that have the potential to revolutionize the healthcare industry.